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Abstract 
Aim 
Prisoners exhibit high rates of substance use and mental health problems. In the 
present study we sought to gain detailed understanding of substance use among young 
prisoners to inform early detection and early intervention strategies in a prison setting. 
Methods 
This is a cross-sectional study of 2,102 prisoners who were screened by the London 
Early detection And Prevention in prison team (LEAP).  Data on the use of substances 
were collected including age of first use, recent use, duration of use and poly-drug 
use. The Prodromal Questionnaire Brief version was used to screen for the at risk 
mental state. 
Results 
We found high rates of lifetime and recent use and low age of first use of a number of 
substances.  We also found strong associations between substance use and screening 
positive for an at risk mental state.  Logistic regression analysis confirmed that use of 
any drug in the last year, poly-drug and early use, as well as heavy alcohol use, were 
related to an increased risk of screening positive. 
Conclusions 
Substance use in the prison population is not only widespread and heavy but is also 
strongly linked with a higher risk of developing mental health problems.  The need for 
early detection and early intervention in prison is discussed. 
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Introduction 
In many countries the prison population has doubled in sized in the last two decades 
and over 10.2 million people are imprisoned worldwide1. A large systematic review 
and meta-analysis reported a pooled prevalence of 4% for psychosis, 10-12% for 
depression and 40-70% for personality disorders among prisoners2.  Substance misuse 
and dependence are also highly prevalent among prisoners: abuse of drugs was 
between 10% and 60%, and of alcohol between 10% and 30%3. Furthermore, illegal 
substances are available in prison: 30% of British prisoners say that it is easy or very 
easy to get illegal drugs4.  
Strong recommendations have been made for more effective screening tools for drug 
use and for mental health problems to identify prisoners at risk and to provide more 
services for those seeking treatment while imprisoned5. A possible solution for this 
unmet need is the introduction of early detection and early intervention services in 
prison6. In the community, evidence suggests that early detection is effective in 
identifying people at risk of developing psychosis7 and that early intervention could 
prevent the transition to psychosis in some cases8, or at least reduce the duration of 
untreated psychosis9. Early detection services worldwide rely on an individual to be 
help-seeking to access screening and treatment, but prisoners do not routinely access 
health or mental health services in the community10. However they do accept health 
services during their time in custody11.  Our previous work demonstrated that 
prisoners can be screened for the at risk mental state of psychosis and are keen to 
accept early intervention while in prison12-15. In light of the high reported levels of 
substance use amongst young in the period prior to their imprisonment14, 15, in the 
present study we sought to gain detailed understanding of substance use among young 
prisoners to inform early detection and early intervention strategies in this setting.  
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We were particularly interested not just in assessing the use of substances, but also the 
characteristics of substance use associated with poorer health outcomes in community 
samples, such as age of first use, recent use, and poly-drug use16-19.  Our secondary 
aim was to investigate the association between these characteristics and screening 
positive on the Prodromal Questionnaire Brief version.   
 
Methods 
Setting 
Data were collected in two male prisons in London: a local male prison with a 
capacity of approximately 800 men aged 21 and over who were awaiting trial or on 
short sentences, and a Young Offender Institution (YOI) with approximately 620 
sentenced prisoners aged 18 to 25.   
 
Procedure 
Data used in this study were collected by the London Early detection And Prevention 
in prison (LEAP) Team (this was previously Outreach and Support in South London 
in Prison but changed its name to extend early detection and intervention to all 
emerging mental health problems, not just high risk for psychosis). In line with other 
early detection teams in the community, LEAP screens all new prisoners under 35 
years upon reception into prison for early detection of at risk mental states for 
emerging metal health problems12-14. 
 
Sample 
Prisoners were screened within the first few weeks of arriving to prison. At the YOI 
we aimed to screen all prisoners (aged 18-25); in the adult prison they were aged 21-
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40 for the first six months of the study (in total 95 prisoners screened were 36 years 
old or older) followed by ages 21-35 for the remaining duration (to match it to the age 
of OASIS, the local community service for people with an at risk mental state for 
psychosis20. We excluded only prisoners who had a history of established mental 
health problems before coming to prison and those who had insufficient English to 
answer the screening questions.  
 
Ethical approval 
An Audit and Service Evaluation approval was obtained from the South London and 
Maudsley NHS Foundation Trust to analyse the data collected as part of the routine 
clinical screening offered by LEAP. 
 
Measures 
Socio demographic 
Participants were initially asked about their socio-demographic background to collect 
information on age, self-ascribed ethnicity, country of birth, employment status before 
prison (e.g. student, part time unpaid, full time paid), accommodation (e.g. live with 
family, house/flat that you rent, homeless), age left full-time education and highest 
qualification achieved. 
 
Substance use 
The modified version of the Cannabis Experience Questionnaire (CEQ21, 22) was used 
to elicit detailed information on drug use. The psychometric properties of this 
instrument have been established 21 and the CEQ has been used extensively to assess 
substance use in people with schizotypy 21; at risk mental state for psychosis 19, and 
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psychosis 18, 22, 23. The advantage of the CEQ above other similar measures is that it 
enables the assessment of lifetime use of substances as well as measuring for each 
substance previously used: age of first use, last use, frequency of use in last month, 
and level of current use if applicable.  
Participants were defined as being current users of a substance if they reported any 
use in the preceding month, and recent users if they reported use in the preceding 
year. Any use before the age of 15 years was defined as ‘early-onset’16. The use of the 
following substances was assessed commercial weed or hash, skunk, inhalants, crack 
cocaine, powder cocaine, stimulants, sedatives, opioids and hallucinogens. There was 
an additional category for ‘other’ that covers new psychoactive substances (e.g. 
synthetic cannabis, mephedrone) as these were not as prevalent when the 
questionnaire was designed although their use has since become substantial. The 
glossary in figure 1 contains a definition of the substances assessed.   
 
-- Figure 1 -- 
 
Alcohol use  
Five questions were used to assess alcohol use, 1) drinks alcohol; 2) age of first drink; 
3) number of units prior to prison; 4) frequency from never to daily/almost daily; 5) 
frequency of five or more drinks from never to daily/almost daily. The weekly 
maximum allowance for alcohol for men as recommended by the NHS is 3-4 units per 
day (www.nhs.uk/conditions/alcohol-misuse) so we used five or more drinks daily or 
almost daily as the cut-off point for excessive drinking. 
 
Prodromal Questionnaire-Brief Version  
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The Prodromal Questionnaire – Brief Version (PQ-B)24, was adapted to maximise 
sensitivity and specificity and to minimise the risk of participants misunderstanding 
the screening questions, and it is established to be an effective tool for a prison 
sample13.  Screening positive on the PQ-B indicates the possibility of an at risk mental 
state for psychosis and the need for further assessment. Our previous findings, 
demonstrate that the PQ-B is also effective in detecting people with other emerging 
and established mental health12-14. 
 
Analyses 
IBM SPSS 22 was used to analyse the data.  Variables were computed for recent use 
(use in the last year) and duration of use (for those who had used in the last year).  
Chi-square tests were used to measure associations between use of each substance 
(lifetime and past year) and screen result and poly-drug use and screen result.  
Independent samples t-tests for mean age of first use and mean duration of use were 
calculated.  Due to the high rates of substance use, and the highly significant 
associations with screening positive, we performed a binary logistic regression 
analysis to assess the relative impact of substance use factors deemed, on the basis of 
univariate analysis, to affect mental health outcomes. 
 
Results 
Total sample 
Socio-demographic characteristics 
Our sample of 2,115 comprised 614 from the YOI and 1,501 from the adult prison.  
We excluded 13 participants found to be psychotic at the time of the screening in 
order to look only at emerging mental health issues, bringing the total sample size to 
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2,102. 
Socio-demographic variables are presented in Table 1.  
 
-- Table 1 -- 
 
Substance use  
Lifetime use 
Data on use of substances (without alcohol) are presented in Table 2.  Lifetime use of 
cigarettes was reported by 83.1% of the sample, most of whom had smoked cigarettes 
in the past year.  Of the illegal substances, weed/hash and skunk were the most 
prevalent, with 78% and 72.9% respectively having used at some time in their life and 
over 50% having used in the past year.  Use of class A drugs was high; a third of 
prisoners had used cocaine, over a quarter stimulants and a fifth crack in their 
lifetime.   
 
Recent use 
Across all substances except inhalants, stimulants and hallucinogens, participants who 
had ever used the substance were more likely than not to have used in the past year 
(Table 2).  
 
-- Table 2 --  
 
Age of first use 
For cigarettes, weed/hash the mean age of first use was below 15, and for skunk still 
below 16. For all class A drugs the mean age of first use was above 18 with the 
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exception of hallucinogens for which the mean age of first use was 17  
(Supplementary Table A).  
 
Duration of use 
In those who used in the past year, the mean duration of use for weed/hash and skunk 
was around 10 years, although the standard deviation was high for both.  Crack and 
stimulants had similarly high duration of use.  It should be noted that the duration is 
purely the difference in years between first use and last use, for those who had used in 
the last year, so high mean durations do not reveal the rate of use  (Supplementary 
Table A). 
 
Poly-drug use 
Data for cumulative use of substances excluding tobacco and alcohol revealed that 
15.9% of prisoners had not used any of the 10 substances in their lifetime; 15.2% had 
used six or more and 39.6% had used three or more  (Supplementary Table B). 
A high proportion (69.3%, n=1,457) of participants had used both weed/hash and 
skunk.  One quarter of the total sample had used weed/hash or skunk in combination 
with stimulants (Supplementary Table C) 
More than 89% of those who had ever used crack, cocaine, stimulants and sedatives 
had also used weed/hash and skunk and those who had used any of the class A drugs 
were highly likely to have tried the five other substances.   
 
Alcohol use  
General rates of alcohol use were high (Table 3): 79.2% of the sample said they did 
drink and the mean age of first drink was 15.85 (sd 3.30).  Nearly a fifth (n=398) said 
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they drank daily or almost daily the majority of whom said they had five or more 
drinks daily or almost daily (n=278).   
 
- Table 3 -  
 
Comparison between screen positive and screen negative 
Socio-demographic characteristics  
Those who screened positive on the PQ-B were more likely to: be White British; have 
been unemployed before coming to prison; be homeless; have left school before the 
age of 16 and have no school qualifications (Table 1). 
 
Substance use and screening positive on the PQ-B 
Lifetime use 
Use of each substance was first examined without controlling for the other substances.  
Cross-tabulations between screen outcome and lifetime use of the substances revealed 
that for all substances the group screening positive on the PQ-B were much more 
likely to have used the substance than those testing negative (Table 2).  
 
Recent use 
Not surprisingly, given that the majority of lifetime users had also used substances in 
the past year, positive screens were strongly associated with recent use (Table 2).  
 
Age of first use 
For all substances (except: inhalants, cocaine, hallucinogens and ‘other’), the mean 
age of first use was significantly lower among the group screening positive than 
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screening negative (Supplementary Table A).   
 
Duration of use 
Duration of use for those who had used in the last year was significantly higher in the 
positive group than the negative for all substances except: inhalants, crack, opioids, 
hallucinogens, and ‘other’ (Supplementary Table A).  To some extent this reflects the 
earlier age of first use. 
 
Poly-drug use 
Participants screening positive were much more likely to have tried a greater number 
of drugs  (Supplementary Table B).  Those who used three substances were nearly 
four times more likely to screen positive (95% CI: 2.31-5.49) and those who used 
eight substances were 15 times more likely to screen positive (95% CI: 8.26-25.82). 
Those who screened positive on the PQ-B were also significantly more likely to have 
co-used substances (Supplementary Table C). 
 
Alcohol use 
Prisoners who drank daily or almost daily, and people who had five or more drinks 
daily or almost daily, were much more likely to screen positive.  The mean age for the 
screen positives was almost a year younger than the screen negatives (Table 3).   
 
Association between substance use and screening positive on the PQ-B 
A binary logistic regression analysis was performed to test the association of the 
different substance use characteristics with screening positive (Table 4).  Screen 
outcome (positive or negative) was the dependent variable.  The model used forced 
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entry method and included five independent variables regarding substance use.  
Cigarette use was omitted from these computed variables due to its very high 
prevalence.  Five variables were included based on their association with screening 
positive in chi-square tests of association.  When these variables were included the 
model did not violate the multicollinearity assumption (tolerance values ranged from 
0.41 to 0.94, VIF from 1.06 to 2.47). 
The final model containing all 10 predictors was statistically significant, Χ2 (8, 
n=1765) = 283.35, p < 0.005.  It explained between 14.8% (Cox & Snell R square) 
and 20.8% (Nagelkerke R square) of the variance in screen outcome and classified 
74.3% of cases correctly.   
This model was able to correctly identify 36.6% of cases as positive at screen, and 
91.9% of negative at screen.  The low sensitivity suggests this model needs to be 
refined but the considerable significance of most of our substance use variables 
supports the hypothesis that drug and alcohol use is strongly associated with 
screening positive on the PQ-B.  
 
- Table 4 - 
 
Discussion 
Substance use and mental health problems are comment in young prisoners 
The use of a range of substances including alcohol was very high in this sample and 
there was a clear association with screening positive on the PQ-B. These findings are 
consistent with previous research, which has shown that substance use and 
dependence are high in prison populations3, 25-27.  Use was particularly high, both 
lifetime and past year, for alcohol, cigarettes, weed/hash and skunk, but also for some 
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class A drugs, and alcohol use was extremely widespread and in many cases heavy.  
Most prisoners had used more than one illegal substance in their lifetime the majority 
of whom continued to use substances in the previous year and reported continued use 
over several years. 
Cigarette smoking was very prevalent and people were still in smoking while in 
prison. This not only has obvious negative consequences for physical health, but is 
also interesting in light of recent findings suggesting that smoking cigarettes may be 
associated with an increase of psychosis28. 
 
The case for early detection and early intervention in prison settings 
Our results support the need for early detection and inform the implementation of 
early intervention programs in prison, for both substance use and mental health 
problems6. Use of illicit substances can have a number of adverse effects mental 
health29 and substance dependence and mental disorder often appear together30.  
Within the prison population, psychosis particularly is found to co-occur with drug 
use26 and more severe offending has been found to be associated with drug abuse and 
alcohol abuse31.  Studies into the effects of cannabis use on mental health outcomes in 
non-prison samples suggest that it is greater amounts and duration of use and lower 
age of first use that make the individual more vulnerable to its harmful effects23, 32, 33.  
Consistent with this we found that participants were significantly more likely to 
screen positive on the PQ-B if they reported lifetime use of any substance, but also if 
they had: used in the last year, if they had used the substance more recently or for a 
longer duration, if they started using at a younger age and if they had used more than 
one substance.   
The logistic regression model was significant overall and confirmed that several 
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substance use characteristics were linked with a positive screen result: use of any 
substance in the last year, lowest age of first use of any substance, heavy alcohol use 
and poly-drug use.  However the low sensitivity suggests that the model needs to be 
refined.  
These results are particularly significant because of the paucity of studies of this size 
of drug use in UK prisoners.  The rates of substance use alone are cause for concern; 
compounded with this is the mental ill-health, the impact of both substance use and 
mental ill-health on offending behaviour, and the implications for the health and 
criminal justice systems and for wider society.  The overall reoffending rate for adults 
released from custody is almost 50% but in general reoffending is higher for people 
under 35 and particularly high among young offenders 
(https://www.gov.uk/government/collections/reoffending-statistics).  Effective drug 
policy needs to encompass not only better controls but also more effective treatment 
interventions for drug use as well as for the co-occurring mental health problems34.  
Research shows that drug treatment services can significantly reduce a range of 
problem behaviours35.  However less than half of prisons have a specialist service for 
substance misuse, despite the high levels of dependence in prisons, and the standard 
and availability of services is inadequate to meet the need 36. Furthermore, to our 
knowledge, our service is the only one worldwide dedicated to the early detection and 
early intervention of young prisoners.  These findings support recommendations to 
improve access to substance dependency programmes in prisons and to forge better 
links between substance use and mental health support services and established care 
pathways, but furthermore to implement more effective and well-evidenced screening 
and intervention tools which take full account of the role of substance use to identify 
prisoners with emerging mental health problems. 
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Integrating early intervention in prison 
Introducing early detection screening in prison is not without challenges.  The current 
UK prison system the assessment of mental health problems at reception is limited 
(First Reception Health Screen, based on the Grubin model 37)  and focuses on asking 
about existing mental health problems. Early detection has to work integrated with the 
prison regime in order to be successful. The prison where LEAP works receives 
around 95 sentenced prisoners every month aged 18 to 30 years old. The prison 
regime allows us to approach prisoners daily only between 10am and 12pm and 
between 2pm and 430pm.  Over the years we have developed and validated a two 
stage screening procedure, which fits within the prison regime and works closely with 
the existing mental health teams. The initial stage is limited to a maximum of 30 
minutes and collects information about; demographics; prodromal symptoms; 
previous traumatic experiences (childhood separation; history of physical or sexual 
abuse; victim of violence or crime); risk of self-harm and history of self-harm; and 
recent and previous substance use including alcohol 13, 14. Participants who screen 
positive are assessed using the Comprehensive Assessment of the At Risk Mental 
State 38. Both the screening and the CAARMS can be administered by a trained 
mental health worker. In LEAP we have found promising engagement and motivation 
following referral to psychological therapy. Ninety percent of the young men in 
prison we have offered psychological interventions to engaged well. However, we 
have found that a flexible “here and now” approach appropriate for people with low 
educational attainment is needed12, 39. 
 
Limitations 
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A more detailed picture of patterns of drug use could be gained by collecting data on 
use of substances within the previous month rather than just the past year, but it was 
not possible in this case to clarify whether time spent in prison was included.  In 
addition the study relies on prisoners accurately reporting their own use of substances, 
so levels of use could be inaccurate and the strengths and amounts of the substances 
not be comparable.  However this is an issue with any self-report study and the high 
rates seem to indicate truthfulness.  In terms of detecting mental health issues, 
screening positive does not guarantee that the individual has a mental disorder, only 
that they need further assessment showing signs of an emerging mental health 
problem.  However the sample size lends power, the significance levels of all the tests 
of association argue for reliability, and the regression analysis support this.   
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Table 1. Demographics of the total sample and association with screen result. 
 
 Total 
2102 
n (%) 
Negative  
1499 
n (%) 
Positive  
603 
n (%) 
Test statistic 
 
Mean age, years (sd) 
 
25.80 (5.33) 
 
25.42 (5.221) 
 
26.75 (5.493) t=-5.094 
 
p<.001 
 
Ethnicity  
  
 
 
Χ2=36.19 
 
p<.001 
    Black British 400 (19.0) 296 (19.7) 104 (17.2)   
    Black African/Caribbean 600 (28.5) 438 (29.2) 162 (26.9)   
    White British 513 (24.2) 323 (21.5) 190 (31.5)   
    White other 149 (7.1) 115 (7.7) 34 (5.6)   
    Mixed 201 (9.6) 133 (8.9) 68 (11.3)   
    Other 239 (11.4) 194 (12.9) 45 (7.5)   
 
Occupation  
 
 
  
Χ2=35.84 
 
p<.001 
    Paid employed 643 (30.6) 504 (33.6) 139 (23.1)   
    Unemployed 1041 (49.5) 685 (45.7) 356 (59.0)   
    Student 299 (14.2) 229 (15.3) 70 (11.6)   
    Other 119 (5.7) 81 (5.4) 38 (6.3)   
 
Accommodation  
 
 
  
Χ2=68.68 
 
p<.001 
    Fixed abode 1420 (67.6) 1047 (69.9) 373 (61.9)   
    Temp. accommodation 458 (21.8) 310 (20.7) 148 (24.5)   
    Homeless 120 (5.7) 51 (3.4) 69 (11.4)   
    Other 103 (4.9) 90 (6.0) 13 (2.2)   
    Missing 1 1    
 
Age education ended  
 
 
   
Χ2=46.84 
 
p<.001 
    </=13 142 (6.8) 86 (5.7) 56 (9.3)   
    14-15 525 (25.0) 330 (22.0) 195 (32.3)   
    16-17 754 (35.9) 545 (36.4) 209 (34.7)   
    18-20 449 (21.4) 351 (23.4) 98 (16.3)   
    >\=21 
    Missing 
 
232 (11.0) 
18 
187 (12.5) 
13 
45 (7.5) 
5 
  
Highest qualification    Χ2=33.93 p<.001 
    None 558 (26.6) 360 (24.2) 198 (32.9)   
    GCSE/O Level 414 (19.7) 309 (20.8) 105 (17.4)   
    Vocational courses 167 (7.9) 126 (8.5) 41 (6.8)   
    NVQ/City & Guilds 533 (25.4) 369 (24.8) 164 (27.2)   
    A Level/Diploma 205 (9.8) 160 (10.7) 45 (7.5)   
    Degree 89 (4.2) 69 (4.6) 20 (3.3)   
    Other 124 (5.9) 95 (6.4) 29 (4.8)   
    Missing 
 
12 11 1   
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Table 2.  Use of substances and association with screen result. 
 
 Used in lifetime  Used in past year 
Substance Total Negative 
n (%) 
Positive 
n (%) 
Χ2 
p 
OR  
(95%CI) 
 Total Negative 
n (%) 
Positive 
n (%) 
 
Χ2 
p 
OR 
(95%CI) 
Cigarettes 1746 
(83.1) 
1196 
(79.8) 
550 
(91.2) 
39.59 
<.001 
2.68 
(1.92-3.57) 
 1618  
(77.0) 
1091 
(72.8) 
527 
(87.4) 
51.82 
<.001 
2.59 
(1.99-3.38) 
Weed/Hash 1639 
(78.0) 
1109 
(74.0) 
530 
(87.9) 
48.16 
<.001 
2.55 
(1.94-3.34) 
 1075 
(51.1) 
670 
(44.7) 
405 
(67.2) 
86.87 
<.001 
2.53 
(2.08-3.09) 
Skunk 1533 
(72.9) 
1020 
(68.1) 
513 
(85.1) 
62.87 
<.001 
2.67 
(2.08-3.43) 
 1088 
(51.8) 
680 
(45.4) 
408 
(67.7) 
85.63 
<.001 
2.52 
(2.07-3.07) 
Inhalants 139 
(6.6) 
45 
(3.0) 
94 
(15.6) 
110.21 
<.001 
5.96 
(4.12-8.63) 
 11 
(0.5) 
3 
(0.2) 
8 
(1.3) 
10.48 
.001* 
6.71 
(1.77-25.36) 
Crack 431 
(20.5) 
205 
(13.7) 
226 
(37.5) 
149.28 
<.001 
3.78 
(3.03-4.72) 
 253 
(12.0) 
110  
(7.3) 
143 
(23.7) 
108.93 
<.001 
3.93 
(3.00-5.14) 
Cocaine 706 
(33.6) 
405 
(27.0) 
301 
(49.9) 
100.89 
<.001 
2.69 
(2.21-3.28) 
 381 
(18.1) 
198 
(13.2) 
183 
(30.3) 
85.12 
<.001 
2.86 
(2.28-3.60) 
Stimulants 576 
(27.4) 
308 
(20.6) 
268 
(44.4) 
123.24 
<.001 
3.09 
(2.52-3.79) 
 158 
(7.5) 
76  
(5.1) 
82 
(13.6) 
44.99 
<.001 
2.95 
(2.12-4.09) 
Sedatives 339  
(16.1) 
134 
(8.9) 
205 
(34.0) 
199.40 
<.001 
5.24 
(4.11-6.70) 
 235 
(11.2) 
81 
(5.4) 
154 
(25.5) 
175.57 
<.001 
6.00 
(4.50-8.02) 
Opioids 275 
(13.1) 
117 
(7.8) 
158 
(26.2) 
127.84 
<.001 
4.19 
(3.23-5.45) 
 203 
(9.7) 
86  
(5.7) 
117 
(19.4) 
92.05 
<.001 
3.96 
(2.94-5.32) 
Hallucin- 
ogens 
256 
(12.2) 
112 
(7.5) 
144 
(23.9) 
108.12 
<.001 
3.88 
(2.97-5.08) 
 23 
(1.1) 
8 
(0.5) 
15 
(2.5) 
15.17 
<.001 
4.75 
(2.01-11.27) 
Other 238 
(11.3) 
87 
(5.8) 
151 
(25.0) 
158.34 
<.001 
5.42 
4.08-7.20 
 165 
(7.9) 
60 
(4.0) 
105 
(17.4) 
106.91 
<.001 
5.06 
(3.62-7.06) 
 
*cell has expected count less than five 
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Table 3 Alcohol use and association with screen result.  
 
 Total 
 
Negative 
 
Positive 
 
Test statistic Sig 
Do you drink alcohol? 1664 (79.2) 1157 (77.2) 507 (84.1) Χ2 =	12.22 <.001 
 
Age of first drink 
 
n=1735 
 
n=1207 
 
n=528 
 
 
   Mean (sd) 15.85 (3.30) 16.12 (3.15) 15.22 (3.53) t (909df)= 5.08 <.001 
      
How often do you drink? n=2100 n=1497 n=603 Χ2 =	176.50 <.001 
   Never  524 (25.0) 398 (26.6) 126 (20.9)   
   Less than monthly 211 (10.0) 164 (11.0) 47 (7.8)   
   Once a month 199 (9.5) 162 (10.8) 37 (6.1)   
   2 or 3 times a month 279 (13.3) 221 (14.8) 58 (9.6)   
   Weekly 493 (23.5) 373 (24.9) 120 (19.9)   
   Daily/almost daily 398 (18.8) 179 (12.0) 215 (35.7)   
      
How often do you have 
five or more drinks? 
 
n=2099 
 
n=1496 
 
n=603 
 
Χ2 =	61.78 
 
<.001 
   Never 869 (41.4) 661 (44.1) 208 (34.5)   
   Less than monthly 357 (17.0) 278 (18.6) 79 (13.1)   
   Monthly 244 (11.6) 191 (12.8) 53 (8.8)   
   Weekly 351 (16.7) 251 (16.8) 100 (16.6)   
   Daily/almost daily 278 (13.2) 115 (7.7) 163 (27.0)   
 
 
Table 4.  Results of binary logistic regression analysis. 
 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Substance use         
  Use of any substance in last year .744 .165 20.316 1 .000 2.105 1.523 2.909 
  Five or more units daily or almost daily .887 .153 33.675 1 .000 2.427 1.799 3.274 
  Highest duration of any substance used .002 .012 .023 1 .880 1.002 .978 1.027 
  Lowest age any substance used -.082 .022 14.053 1 .000 .921 .882 .961 
  Number of drugs used .213 .032 45.729 1 .000 1.238 1.164 1.317 
Socio-demographic         
  Ethnicity White British -.386 .140 7.576 1 .006 .680 .516 .895 
  Occupation unemployed .123 .118 1.090 1 .296 1.131 .898 1.423 
  Accommodation homeless/ temporary .184 .125 2.166 1 .141 1.202 .941 1.535 
  Education ended before age 16 .061 .127 .230 1 .632 1.063 .828 1.364 
  Qualifications none .062 .130 .230 1 .632 1.064 .825 1.374 
Note: Model X2 (10, n=1765) = 283.35, p<0.001. R2 = .148 (Cox & Snell), .208 (Nagelkerke). 
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Figure 1. Drugs Glossary 
 
 
 
 
Weed or hash: traditional herbal marijuana and hashish 
Skunk: high potency cannabis 
Inhalants: e.g. glue, petrol, gas, poppers 
Crack cocaine: crystalline form of cocaine  
Powder cocaine: drug obtained from coca leaves 
Stimulants e.g  amphetamines, ecstasy 
Sedatives e.g. benzodiazepines; barbiturates 
Opioids e.g heroin, morphine, methadone 
Hallucinogens: e.g. LSD (lysergic acid diethylamide), Magic Mushrooms 
Other: covers new psychoactive substances e.g. spice or synthetic cannabis, 
mephedrone, ketamine 
 
Under the Misuse of Drugs Act 1971, illegal drugs are placed into one of 3 classes - 
A, B or C. This is broadly based on the harms they cause either to the user or to 
society when they are misused. 
• Class A drugs include: heroin, cocaine (including crack), methadone, ecstasy 
(MDMA), LSD, and magic mushrooms. 
• Class B includes: amphetamines, barbiturates, codeine, cannabis, cathinones 
(including mephedrone) and synthetic cannabinoids. 
• Class C includes: benzodiazepines (tranquilisers), GHB/GBL, ketamine, anabolic 
steroids and benzylpiperazines (BZP). 
 
For more information please visit http://www.talktofrank.com 
